LA JOLLA, Calif.--(BUSINESS WIRE)--Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145. Intellikine licensed development and commercialization rights for IPI-145, a potent, orally available inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, to Infinity Pharmaceuticals, Inc. in July 2010.
